Although lecanemab has been licensed for use in the UK, the systems to deliver this or similar disease-modifying therapies do not exist. These systems need to be developed urgently, but not at the expense of post-diagnostic care.

尽管lecanemab已在英国获得使用许可，但尚不存在提供这种或类似疾病缓解疗法的系统。。

Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journalsGet Nature+, our best-value online-access subscription24,99 € / 30 dayscancel any timeLearn moreSubscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.comBuy this articlePurchase on SpringerLinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout.

Access Nature和54篇其他Nature Portfolio journalsGet Nature+，我们最有价值的在线订阅24,99欧元/30天，随时为中国客户获取更多订阅信息我们为中国客户提供了一个专门的网站。请访问naturechina.com订阅本期刊。访问naturechina.comBuy本文在Springerlink上购买即时访问完整文章PDFBuy Now价格可能需要缴纳结帐时计算的地方税。

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

ReferencesMedicines and Healthcare products Regulatory Agency. Lecanemab Licensed for Adult Patients in the Early Stages of Alzheimer’s Disease https://www.gov.uk/government/news/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease (2024).National Institute for Health and Care Excellence.

参考药品和保健品管理局。Lecanemab许可用于阿尔茨海默病早期的成年患者https://www.gov.uk/government/news/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease（2024年）。。

Benefits of New Alzheimer’s Treatment Lecanemab are Too Small to Justify the Cost to the NHS. https://www.nice.org.uk/news/articles/benefits-of-new-alzheimer-s-treatment-lecanemab-are-too-small-to-justify-the-cost-to-the-nhs (2024).van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl.

新的阿尔茨海默氏病治疗剂莱卡单抗的益处太小，无法证明NHS的成本是合理的。https://www.nice.org.uk/news/articles/benefits-of-new-alzheimer-s-treatment-lecanemab-are-too-small-to-justify-the-cost-to-the-nhs（2024）。van Dyck，C.H。等人。早期阿尔茨海默病中的Lecanemab。N、 英语。

J. Med. 388, 9–21 (2023).PubMed .

《医学杂志》，388，9-21（2023）。PubMed。

Google Scholar

谷歌学者

Dobson, R. et al. Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 95, 796–803 (2024).PubMed

Dobson，R.等人，《抗淀粉样蛋白治疗的资格：为阿尔茨海默病的疾病缓解疗法做准备》。J、 神经病学。神经外科精神病学95796-803（2024）。PubMed出版社

Google Scholar

谷歌学者

Anandaciva, S. How does the NHS compare to the health care systems of other countries? The King’s Fund https://www.kingsfund.org.uk/insight-and-analysis/reports/nhs-compare-health-care-systems-other-countries (2023).What are the costs of dementia diagnosis and care in the UK? Alzheimer’s Society https://www.alzheimers.org.uk/about-us/policy-and-influencing/dementia-scale-impact-numbers (2024).National Institute for Health and Care Excellence.

Anandaciva，S。NHS与其他国家的医疗保健系统相比如何？国王基金https://www.kingsfund.org.uk/insight-and-analysis/reports/nhs-compare-health-care-systems-other-countries（2023年）。英国痴呆症诊断和护理的费用是多少？阿尔茨海默病学会https://www.alzheimers.org.uk/about-us/policy-and-influencing/dementia-scale-impact-numbers（2024年）。。

Dementia: Assessment, Management and Support for People Living with Dementia and their Carers https://www.nice.org.uk/guidance/ng97/chapter/Recommendations (2018).Eaglestone, G. et al. Cost-effectiveness of non-pharmacological interventions for mild cognitive impairment and dementia: a systematic review of economic evaluations and a review of reviews.

痴呆症：对痴呆症患者及其护理人员的评估、管理和支持https://www.nice.org.uk/guidance/ng97/chapter/Recommendations（2018年）。Eaglestone，G.等人，《轻度认知障碍和痴呆的非药物干预的成本效益：经济评估的系统评价和评论评论》。

PharmacoEconom. Open 7, 887–914 (2023)..

药物经济学。开放式7887–914（2023）。。

Google Scholar

谷歌学者

Ballard, C. et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: a cluster-randomised controlled trial. PLoS Med. 15, e1002500 (2018).PubMed

Ballard，C.等人，《以人为中心的护理培训和以人为中心的活动对养老院痴呆症患者生活质量，激动和抗精神病药物使用的影响：一项整群随机对照试验》。PLoS Med.15，e1002500（2018）。PubMed出版社

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Isaaq, A. et al. Cost-utility of a new psychosocial goal-setting and manualised support intervention for Independence in Dementia (NIDUS-Family) versus goal-setting and routine care: economic evaluation embedded within a randomised controlled trial. Preprint at https://www.medrxiv.org/content/10.1101/2024.08.24.24312530v1 (2024).Download referencesAuthor informationAuthors and AffiliationsWolfson Institute of Population Health, Queen Mary University of London, London, UKClaudia Cooper & Charles R.

Isaaq，A.等人，《新的心理社会目标设定和手动支持干预痴呆症独立性（NIDUS家庭）与目标设定和常规护理的成本效用：嵌入随机对照试验的经济评估》。预印于https://www.medrxiv.org/content/10.1101/2024.08.24.24312530v1（2024年）。下载参考文献作者信息作者和附属机构伦敦玛丽女王大学沃尔夫森人口健康研究所，英国克劳迪亚·库珀和查尔斯·R。

MarshallInstitute of Neurology, Faculty of Brain Sciences, University College London, London, UKJonathan M. SchottFaculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UKSube BanerjeeAuthorsClaudia CooperView author publicationsYou can also search for this author in.

英国伦敦大学学院脑科学学院马歇尔神经病学研究所Jonathan M.Schott英国诺丁汉大学诺丁汉分校医学与健康科学学院作者Claudia CooperView作者出版物您也可以在中搜索该作者。

PubMed Google ScholarCharles R. MarshallView author publicationsYou can also search for this author in

PubMed Google ScholarCharles R.MarshallView作者出版物您也可以在

PubMed Google ScholarJonathan M. SchottView author publicationsYou can also search for this author in

PubMed Google ScholarJonathan M.SchottView作者出版物您也可以在

PubMed Google ScholarSube BanerjeeView author publicationsYou can also search for this author in

PubMed Google ScholarSube BanerjeeView作者出版物您也可以在

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

Claudia Cooper.Ethics declarations

克劳迪娅·库珀。道德宣言

Competing interests

相互竞争的利益

C.R.M. has consulted for Roche and is NHS (London) Clinical Director for dementia. J.M.S. has consulted for AVID, Biogen, Eli Lilly, GE, Merck and Roche and is Chief Medical Officer for Alzheimer’s Research UK. He is supported by the NIHR UCL/H Biomedical Research Centre. S.B. has held the following positions: Non-Executive Director Somerset NHS Foundation Trust, Trustee of the Alzheimers Society, Executive Dean of the University of Plymouth, and Pro-Vice Chancellor of the University of Nottingham.

C、 R.M.曾为罗氏咨询，是NHS（伦敦）痴呆症临床主任。J、 M.S.曾为AVID、Biogen、Eli Lilly、GE、Merck和Roche提供咨询，并且是英国阿尔茨海默病研究的首席医疗官。他得到了NIHR UCL/H生物医学研究中心的支持。S、 B.曾担任以下职务：萨默塞特NHS基金会信托非执行董事、阿尔茨海默病学会受托人、普利茅斯大学执行院长和诺丁汉大学副校长。

He has acted as a consultant and in an educational role for Lilly and Lundbeck. C.C. is Chief investigator of the Alzheimer’s society NIDUS programme..

他曾担任礼来和伦贝克的顾问和教育角色。C、 C.是阿尔茨海默氏病学会巢穴计划的首席研究员。。

Rights and permissionsReprints and permissionsAbout this articleCite this articleCooper, C., Marshall, C.R., Schott, J.M. et al. Preparing for disease-modifying dementia therapies in the UK.

权利和许可打印和许可本文引用本文Cooper，C.，Marshall，C.R.，Schott，J.M.等人在英国准备改善疾病的痴呆疗法。

Nat Rev Neurol (2024). https://doi.org/10.1038/s41582-024-01022-1Download citationPublished: 17 September 2024DOI: https://doi.org/10.1038/s41582-024-01022-1Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

。https://doi.org/10.1038/s41582-024-01022-1Download引文发布日期：2024年9月17日OI：https://doi.org/10.1038/s41582-024-01022-1Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供